Lentigo maligna melanoma (LMM)
Also known as: Lentigo maligna melanoma
Methodology & AI Transparency ⓘ
Lentigo maligna melanoma (LMM) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Lentigo maligna melanoma (LMM) uses ICD-10 C43.9 across Cancer & Oncology specialty care.
- 3 Typical cash cost range: Clinicians assessing Lentigo maligna melanoma (LMM) focus on microenvironment inflammation [Lentigo maligna melanoma (LMM) C43.9] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Lentigo maligna melanoma (LMM) monitoring tracks Pathology / Molecular in Lentigo maligna melanoma (LMM) (C43.9: Genomic Staging) toward Guideline-concordant surveillance (C43.9).
Ask our AI Specialists anything about Lentigo maligna melanoma (LMM)
What Is Lentigo maligna melanoma (LMM)?
Recognized across U.S. clinical coding as C43.9 (Cancer & Oncology), Lentigo maligna melanoma (LMM) (also termed Lentigo maligna melanoma) is evaluated via immunohistochemistry [Lentigo maligna melanoma (LMM) C43.9] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
In Lentigo maligna melanoma (LMM) (C43.9), physiological disruption stems from microenvironment inflammation [Lentigo maligna melanoma (LMM) C43.9], informing Cancer, Oncology & Supportive Care protocols that track Complete Blood Count in Lentigo maligna melanoma (LMM) (C43.9: (ANC, Hemoglobin, Platelets)) (Safe hematologic reserve (C43.9)).
Common Symptoms & Clinical Signs
- • Presentation of Lentigo maligna melanoma (LMM) (C43.9): unexplained bleeding, chronic in Lentigo maligna melanoma (LMM) (C43.9: hoarseness/cough, or progressive)
- • Secondary Lentigo maligna melanoma (LMM) clinical sign: abnormality detected early in Lentigo maligna melanoma (LMM) (C43.9: on age-appropriate screening)
- • Symptom flares in Lentigo maligna melanoma (LMM) correlating with Pathology / Molecular in Lentigo maligna melanoma (LMM) (C43.9: Genomic Staging) deviation outside Guideline-concordant surveillance (C43.9)
- • Functional cancer & oncology impact requiring immunohistochemistry [Lentigo maligna melanoma (LMM) C43.9] evaluation (C43.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Lentigo maligna melanoma (LMM) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C43.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Lentigo maligna melanoma (LMM) (C43.9: Genomic Staging) | Guideline-concordant surveillance (C43.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Lentigo maligna melanoma (LMM) (C43.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C43.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Lentigo maligna melanoma (LMM) (C43.9: Organ Function Panel) | Preserved renal/hepatic clearance (C43.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Lentigo maligna melanoma (LMM)
Treatment selection for Lentigo maligna melanoma (LMM) depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lentigo maligna melanoma (LMM))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of imiquimod in the management of lentigo: What a 283-Participant Study Found Imiquimod reduces the lentigo maligna surface after 1 month of treatment, without a higher risk of intralesional excision and with a positive aesthetic outcome. Journal of the European Academy of Dermatology and Venereology : JEADV • 2023-09-15 • Phase III Randomized Trial | N = 283 | 93/100 | PMID 37114291 ↗ |
| Can This Approach Help? Inside the Latest Research on Influence of different photobiomodulation protocols on the prevention of Protocols R or IR proved to be inferior to the R + IR laser photobiomodulation protocol. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer • 2025-07-14 • Phase III Randomized Trial | N = 60 | 88/100 | PMID 40658227 ↗ |
| Can This Approach Help? Inside the Latest Research on Prognostic value of patient-reported outcomes in advanced or metastatic melanoma PROs at baseline and during treatment, particularly for physical functioning, GHS/QoL, fatigue, and EQ-VAS, were prognostic of survival outcomes. European journal of cancer (Oxford, England : 1990) • 2024-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39520835 ↗ |
| Can This Approach Help? Inside the Latest Research on Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with From the perspective of Chinese healthcare system, the SC was not cost-effective in comparison to PC as first-line treatment for NSCLC, regardless of PD-L1 tumor expression level and pathological subtype. Frontiers in public health • 2022-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36408023 ↗ |
| New Insights on Phase III study of short-course radiotherapy combined with Temozolomide in older: What a 270-Participant Study Found Date of Registration: 27/Aug/2020. BMC cancer • 2021-10-15 • Phase III Randomized Trial | N = 270 | 87/100 | PMID 34654402 ↗ |
Lentigo maligna melanoma (LMM) Patient Community & “People Like Me” Threads
Filter Lentigo maligna melanoma (LMM) community threads and patient logs by age, biological sex, dosage, and treatment duration.